Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.
Department of Pharmacy Practice, Midwestern University, Chicago College of Pharmacy, Downers Grove, IL, USA.
J Pharm Pract. 2020 Jun;33(3):243-246. doi: 10.1177/0897190018797767. Epub 2018 Sep 4.
Many patients with a self-reported penicillin allergy go on to tolerate beta-lactam antibiotics. Allergy specialists may be consulted to determine the nature and extent of the allergy. However, electronic allergy records must be appropriately updated such that recommendations are carried forward.
To determine the percentage of patients who have their electronic allergy record updated after an allergy service consult (ASC).
This was a retrospective study of patients with at least 1 documented beta-lactam allergy and had an ASC during (inpatient) or prior to (outpatient) hospital admission at Northwestern Memorial Hospital and Prentice Women's Hospital in Chicago, Illinois.
Within the study period, a total of 26 526 patients were identified as having a documented antibiotic allergy, with 21 657 patients (81.6% of patients with allergies) having a listed beta-lactam allergy. Of these patients, 1689 (7.8%) patients were identified as having an ASC during or prior to admission, with 598 patients meeting inclusion criteria. Changes in the allergy record were recommended by the ASC for 62% (n = 371) of patients; however, the allergy record was updated after the ASC in 74.9% (n = 278) of patients.
ASC recommendations to delabel a patient as beta-lactam allergic must result in updating the allergy record in order to optimize future treatment. Given the low proportion of allergy-labeled patients tested, programs outside formal ASCs should be considered.
许多自述青霉素过敏的患者实际上能够耐受β-内酰胺类抗生素。可能会咨询过敏专科医生以确定过敏的性质和程度。但是,必须适当地更新电子过敏记录,以便将建议延续下去。
确定在过敏专科医生就诊(ASC)后,有多少患者更新了他们的电子过敏记录。
这是一项回顾性研究,研究对象为至少有 1 次记录的β-内酰胺类抗生素过敏史且在西北纪念医院和芝加哥 Prentice 妇女医院住院期间(住院患者)或住院前(门诊患者)接受过 ASC 的患者。
在研究期间,共确定了 26526 名患者存在记录在案的抗生素过敏,其中 21657 名(81.6%的过敏患者)患者有β-内酰胺类过敏记录。在这些患者中,有 1689 名(7.8%的过敏患者)患者在住院期间或住院前接受了 ASC,其中 598 名患者符合纳入标准。ASC 建议改变过敏记录的患者有 62%(n=371),但在 ASC 后有 74.9%(n=278)的患者更新了过敏记录。
ASC 建议将患者从β-内酰胺类过敏标签中删除,必须更新过敏记录,以优化未来的治疗。鉴于接受过敏测试的标记过敏患者比例较低,应考虑在正式 ASC 之外开展相关项目。